{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:12:42Z","timestamp":1793092362907,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100011199","name":"FP7 Ideas: European Research Council","doi-asserted-by":"publisher","award":["FP HEALTH 2013602144"],"award-info":[{"award-number":["FP HEALTH 2013602144"]}],"id":[{"id":"10.13039\/100011199","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12874-018-0475-0","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T12:12:29Z","timestamp":1518091949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Value of information methods to design a clinical trial in a small population to optimise a health economic utility function"],"prefix":"10.1186","volume":"18","author":[{"given":"Michael","family":"Pearce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew Wan","family":"Hee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Posch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Zohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7781-1512","authenticated-orcid":false,"given":"Nigel","family":"Stallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,8]]},"reference":[{"key":"475_CR1","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(08)60876-4","volume":"371","author":"BM Buckley","year":"2008","unstructured":"Buckley BM. Clinical trials of orphan medicines. Lancet. 2008; 371:2051\u20135.","journal-title":"Lancet"},{"key":"475_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-9-1","volume":"9","author":"SA Bell","year":"2014","unstructured":"Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of clinicaltrials.gov. Orhpanet J Rare Dis. 2014; 9:1\u201311.","journal-title":"Orhpanet J Rare Dis"},{"key":"475_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13023-017-0597-1","volume":"12","author":"SW Hee","year":"2017","unstructured":"Hee SW, Willis A, Tudur Smith C, Day S, Miller F, Madan J, Posch M, Zohar S, Stallard N. Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov. Orhpanet J Rare Dis. 2017; 12:44.","journal-title":"Orhpanet J Rare Dis"},{"key":"475_CR4","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1177\/0962280215588245","volume":"25","author":"SW Hee","year":"2016","unstructured":"Hee SW, Hamborg T, Day S, Madan J, Miller F, Posch M, Zohar S, Stallard N. Decision-theoretic designs for small trials and pilot studies: a review. Stat Methods Med Res. 2016; 25:1022\u201338.","journal-title":"Stat Methods Med Res"},{"key":"475_CR5","doi-asserted-by":"crossref","unstructured":"Blanck TJJ, Conahan TJ, Merin RG, Prager RL, Richter JJ. Bayesian Methods and Ethics in a Clinical Trial Design In: Kadane JB, editor. New York: Wiley: 1996. p. 159\u201362.","DOI":"10.1002\/9781118150603.ch9"},{"key":"475_CR6","first-page":"341","volume":"42","author":"K Chaloner","year":"1993","unstructured":"Chaloner K, Church T, Louis TA, Matts JP. Graphical elicitation of a prior distribution for a clinical trial. J R Stat Soc Ser D Stat. 1993; 42:341\u201353.","journal-title":"J R Stat Soc Ser D Stat"},{"key":"475_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1467-9884.00113","volume":"47","author":"J Kadane","year":"1998","unstructured":"Kadane J, Wolfson LJ. Experiences in elicitation. J R Stat Soc Ser D Stat. 1998; 47:3\u201319.","journal-title":"J R Stat Soc Ser D Stat"},{"key":"475_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/pst.1552","volume":"12","author":"N Kinnersley","year":"2013","unstructured":"Kinnersley N, Day S. Structured approach to the elicitation of expert beliefs for a Bayesian-designed clinical trial: a case study. Pharm Stat. 2013; 12:104\u201313.","journal-title":"Pharm Stat"},{"key":"475_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/1467-9884.00114","volume":"47","author":"A O\u2019Hagan","year":"1998","unstructured":"O\u2019Hagan A. Eliciting expert beliefs in substantial practical applications. J R Stat Soc Ser D Stat. 1998; 47:21\u201335.","journal-title":"J R Stat Soc Ser D Stat"},{"key":"475_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/0962280208089298","volume":"18","author":"H Pezeshk","year":"2009","unstructured":"Pezeshk H, Nematollahi N, Maroufy V, Gittins J. The choice of sample size: a mixed Bayesian\/frequentist approach. Stat Methods Med Res. 2009; 18:183\u201394.","journal-title":"Stat Methods Med Res"},{"key":"475_CR11","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1002\/sim.2955","volume":"26","author":"NR Patel","year":"2007","unstructured":"Patel NR, Ankolekar S. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs. Stat Med. 2007; 26:4976\u201388.","journal-title":"Stat Med"},{"key":"475_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11606-014-2880-3","volume":"29","author":"L Abrahamyan","year":"2014","unstructured":"Abrahamyan L, Willan AR, Beyene J, Mclimont M, Blanchette V, Feldman BM. Using value-of-information methods when the disease is rare and the treatment is expensive - the example of hemophilia A. J Gen Intern Med. 2014; 29:767\u201373.","journal-title":"J Gen Intern Med"},{"key":"475_CR13","unstructured":"Orphadata: Rare Diseases Epidemiological Data. INSERM. 1997. http:\/\/www.orphadata.org . Accessed 9 May 2016."},{"key":"475_CR14","unstructured":"The World Bank: Population total. 2016. http:\/\/api.worldbank.org\/v2\/en\/indicator\/SP.POP.TOTL?downloadformat=excel. Accessed 28 Sept 2016."},{"key":"475_CR15","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/biomet\/90.4.923","volume":"90","author":"Y Cheng","year":"2003","unstructured":"Cheng Y, Su F, Berry DA. Choosing sample size for a clinical trial using decision analysis. Biometrika. 2003; 90:923\u201336.","journal-title":"Biometrika"},{"key":"475_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/bimj.201500228","volume":"59","author":"N Stallard","year":"2017","unstructured":"Stallard N, Miller F, Day S, Hee SW, Madan J, Zohar S, Posch M. Determination of the optimal sample size for a clinical trial accounting for the population size. Biom J. 2017; 59:609\u201325.","journal-title":"Biom J"},{"key":"475_CR17","unstructured":"Montazerhodjat V, Lo AW. Is the FDA too conservative or too aggressive? A Bayesian decision analysis of clinical trial design. NBER Working Paper No. 21499 2015. 23 September 2016, http:\/\/www.nber.org\/papers\/w12499."},{"key":"475_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/0272989X04263162","volume":"24","author":"AE Ades","year":"2004","unstructured":"Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modeling. Med Dec Making. 2004; 24:207\u201327.","journal-title":"Med Dec Making"},{"key":"475_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/hec.1161","volume":"16","author":"S Eckermann","year":"2007","unstructured":"Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ. 2007; 16:195\u2013209.","journal-title":"Health Econ"},{"key":"475_CR20","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/sim.3630","volume":"28","author":"T Kikuchi","year":"2009","unstructured":"Kikuchi T, Gittins J. A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety. Stat Med. 2009; 28:2293\u2013306.","journal-title":"Stat Med"},{"key":"475_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2165\/11592250-000000000-00000","volume":"30","author":"AR Willan","year":"2012","unstructured":"Willan AR, Eckermann S. Value of information and pricing new healthcare interventions. Pharmacoeconomics. 2012; 30:447\u201359.","journal-title":"Pharmacoeconomics"},{"key":"475_CR22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1177\/1740774508098413","volume":"5","author":"AR Willan","year":"2008","unstructured":"Willan AR. Optimal sample size determinations from an industry perspective based on the expected value of information. Clin Trials. 2008; 5:587\u201394.","journal-title":"Clin Trials"},{"key":"475_CR23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S0197-2456(97)00098-6","volume":"19","author":"J Hornberger","year":"1998","unstructured":"Hornberger J, Eghtesady P. The cost-benefit of a randomized trial to a health care organization. Control Clin Trials. 1998; 19:198\u2013211.","journal-title":"Control Clin Trials"},{"key":"475_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/sim.703","volume":"20","author":"J Halpern","year":"2001","unstructured":"Halpern J, Brown Jr BW, Hornberger J. The sample size for a clinical trial: a Bayesian-decision theoretic approach. Stat Med. 2001; 20:841\u201358.","journal-title":"Stat Med"},{"key":"475_CR25","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/sim.2069","volume":"24","author":"AR Willan","year":"2005","unstructured":"Willan AR, Pinto EM. The value of information and optimal clinical trial design. Stat Med. 2005; 24:1791\u20131806.","journal-title":"Stat Med"},{"key":"475_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/009286150003400204","volume":"34","author":"J Gittins","year":"2000","unstructured":"Gittins J, Pezeshk H. A behavioral Bayes method for determining the size of a clinical trial. Drug Inf J. 2000; 34:355\u201363.","journal-title":"Drug Inf J"},{"key":"475_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/1467-9884.00228","volume":"49","author":"J Gittins","year":"2000","unstructured":"Gittins J, Pezeshk H. How large should a clinical trial be?J R Stat Soc Ser D Stat. 2000; 49:177\u201387.","journal-title":"J R Stat Soc Ser D Stat"},{"key":"475_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/009286150203600118","volume":"36","author":"H Pezeshk","year":"2002","unstructured":"Pezeshk H, Gittins J. A fully Bayesian approach to calculating sample sizes for clinical trials with binary responses. Drug Inf J. 2002; 36:143\u201350.","journal-title":"Drug Inf J"},{"key":"475_CR29","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/10543406.2014.902851","volume":"24","author":"V Maroufy","year":"2014","unstructured":"Maroufy V, Marriott P, Pezeshk H. An optimization approach to calculating sample sizes with binary responses. J Biopharm Stat. 2014; 24:715\u201331.","journal-title":"J Biopharm Stat"},{"key":"475_CR30","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1002\/sim.6225","volume":"33","author":"LV Hampson","year":"2014","unstructured":"Hampson LV, Whitehead J, Eleftheriou D, Brogan P. Bayesian methods for the design and interpretation of clinical trials in very rare diseases. Stat Med. 2014; 33:4186\u2013201.","journal-title":"Stat Med"},{"key":"475_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2307\/2531909","volume":"44","author":"DA Berry","year":"1988","unstructured":"Berry DA, Ho CH. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach. Biometrics. 1988; 44:219\u201327.","journal-title":"Biometrics"},{"key":"475_CR32","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1080\/01621459.1994.10476893","volume":"89","author":"RT Lewis","year":"1994","unstructured":"Lewis RT, Berry DA. Group sequential clinical trials: A classical evaluation of bayesian decision-theoretic designs. J Am Stat Assoc. 1994; 89:1528\u20131534.","journal-title":"J Am Stat Assoc"},{"key":"475_CR33","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1002\/sim.2638","volume":"25","author":"CR Mehta","year":"2006","unstructured":"Mehta CR, Patel NR. Adaptive, group sequential and decision theoretic approaches to sample size determination. Stat Med. 2006; 25:3250\u201369.","journal-title":"Stat Med"},{"key":"475_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1177\/1740774512467404","volume":"10","author":"MH Chen","year":"2013","unstructured":"Chen MH, Willan AR. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods. Clin Trials. 2013; 10:54\u201362.","journal-title":"Clin Trials"},{"key":"475_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cct.2017.04.010","volume":"59","author":"G Yin","year":"2017","unstructured":"Yin G, Lam CK, Shi H. Bayesian randomized clinical trials: from fixed to adaptive design. Contemp Clin Trials. 2017; 59:77\u201386.","journal-title":"Contemp Clin Trials"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-018-0475-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T22:27:57Z","timestamp":1693520877000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-018-0475-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,8]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["475"],"URL":"https:\/\/doi.org\/10.1186\/s12874-018-0475-0","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,8]]},"assertion":[{"value":"22 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable: no patient data were used in this research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable: no patient data were used in this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"20"}}